Prevention and Reversal of Cholera Enterotoxin Effects in Rabbit Jejunum by Nicotinic Acid

Nabila Turjman, … , Gerald S. Gotterer, Thomas R. Hendrix


Research Article

The cholera enterotoxin produces intestinal secretion associated with an elevation of tissue levels of cyclic adenosine 3’,5’-monophosphate levels of cyclic adenosine 3’,5’-monophosphate (cAMP). The objectives of this study were to determine whether intestinal secretion and cAMP elevation induced by cholera toxin could be prevented, or once initiated, reversed by nicotinic acid, an agent known to lower tissue levels of cAMP. In rabbits, four jejunal loops were constructed as alternating control (3-ml isotonic electrolyte solution) and cholera toxin (same solution containing 50 µg purified cholera toxin) loops. Net intestinal secretion was determined by measuring fluid accumulation, after which intestinal biopsies were taken for cAMP assay. The animals were pretreated either subcutaneously with 50 mg/kg nicotinic acid in saline 3 h and 1 h before the introduction of cholera toxin, or intraluminally with 200 mg/kg nicotinic acid in Ringer’s lactate solution 15 min before the instillation of cholera toxin. Under these conditions, nicotinic acid blocked the cholera toxin-induced secretion and the rise in cAMP measured 3 h after the loops were exposed to cholera toxin. The effect of the nicotinic acid administered within the lumen on net intestinal secretion was studied. Maximal inhibition of net intestinal secretion was achieved with an intraluminally administered dose of nicotinic acid of 100 mg/kg. This dose was chosen for testing the ability of nicotinic acid to […]
Prevention and Reversal of Cholera Enterotoxin Effects in Rabbit Jejunum by Nicotinic Acid

NABILA TURJMAN, GERALD S. GOTTERER, and THOMAS R. HENDRIX, Departments of Physiological Chemistry and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

ABSTRACT The cholera enterotoxin produces intestinal secretion associated with an elevation of tissue levels of cyclic adenosine 3',5'-monophosphate levels of cyclic adenosine 3',5'-monophosphate (cAMP). The objectives of this study were to determine whether intestinal secretion and cAMP elevation induced by cholera toxin could be prevented, or once initiated, reversed by nicotinic acid, an agent known to lower tissue levels of cAMP. In rabbits, four jejunal loops were constructed as alternating control (3-ml isotonic electrolyte solution) and cholera toxin (same solution containing 50 µg purified cholera toxin) loops. Net intestinal secretion was determined by measuring fluid accumulation, after which intestinal biopsies were taken for cAMP assay. The animals were pretreated either subcutaneously with 50 mg/kg nicotinic acid in saline 3 h and 1 h before the introduction of cholera toxin, or intraluminally with 200 mg/kg nicotinic acid in Ringer's lactate solution 15 min before the instillation of cholera toxin. Under these conditions, nicotinic acid blocked the cholera toxin-induced secretion and the rise in cAMP measured 3 h after the loops were exposed to cholera toxin. The effect of the nicotinic acid administered within the lumen on net intestinal secretion was studied. Maximal inhibition of net intestinal secretion was achieved with an intraluminally administered dose of nicotinic acid of 100 mg/kg. This dose was chosen for testing the ability of nicotinic acid to reverse the effects of cholera toxin. When nicotinic acid was instilled into a fifth loop constructed distally to the four experimental loops 3 h after exposure of these loops to cholera toxin, both intestinal secretion and elevation of cAMP were reversed. These results suggest that nicotinic acid can prevent and reverse the secretory effects of cholera toxin and may have a role in the therapy of cholera and other cAMP-associated diarrheal diseases.

INTRODUCTION

It is generally held that cholera enterotoxin (CT) produces intestinal secretion through the activation of intestinal adenylate cyclase with subsequent elevation of cyclic adenosine 3',5'-monophosphate (cAMP) (1). If this view is correct, agents that inhibit adenylate cyclase or prevent elevation of levels of intestinal cAMP should prevent CT-induced secretion. In isolated fat cells studied in vitro, it has been shown that nicotinic acid is effective in preventing the rise in tissue cAMP elicited by a variety of stimuli such as epinephrine, ACTH, and glucagon (2).

The mechanism by which nicotinic acid prevents the rise in cAMP is controversial. Some hold that the effect is the result of the inhibition of adenylate cyclase (3), while others have presented evidence that the effect is the result of the activation of phosphodiesterase (4). Regardless of mechanism, it seemed worthwhile to determine whether CT-induced intestinal secretion and cAMP elevation could be prevented or, once initiated, reversed by nicotinic acid.

The results of the present study demonstrate that nicotinic acid, both by subcutaneous and intraluminal administration, is effective in preventing CT-induced secretion and elevation of tissue cAMP in in vivo jejunal loops of rabbits. In addition, these studies show that nicotinic acid can also reverse these intestinal effects of CT.

METHODS

Prevention of CT-induced changes. To determine the effect of pretreatment with nicotinic acid on CT-induced secretion, we compared net fluid movement and levels of cAMP in


Received for publication 8 August 1977 and in revised form 1 December 1977.

Abbreviations used in this paper: cAMP, cyclic adenosine 3',5'-monophosphate; CT, cholera enterotoxin; RL, Ringer's lactate.
jejunal loops of rabbits pretreated with nicotinic acid and those receiving no drug. Male New Zealand white rabbits weighing between 1.7 to 2.3 kg were anesthetized with 20 mg/kg intravenous sodium pentobarbital after fasting overnight. The small intestine was exposed through a mid-line incision and a drain for duodenal juice was constructed. Four consecutive segments of jejunum measuring approximately 10 cm each in length were isolated with intact blood supply and cannulated. The loops were flushed clean with Ringer's lactate solution, emptied, and replaced in the abdominal cavity. Rectal temperature was monitored and the body temperature was maintained between 37° and 39°C with the aid of a heat lamp. Throughout the study, hydration of the animals was maintained with an intravenous infusion of Ringer's lactate (RL) at the rate of 50–60 ml/h. After a rest period of 1 h after the surgical procedures, a full-thickness intestinal biopsy was taken just distal to the fourth loop for base-line cAMP determination.

In each animal, the four intestinal loops were set up as alternating control loops exposed for 3 h to 3 ml of isotonic electrolyte solution (Na⁺, 150 mM; Cl⁻, 75 mM; and HCO₃⁻, 75 mM), and CT loops similarly exposed to the same solution containing 50 μg purified CT (lot BZ 2487, Schwarz Div., Mann Bector, Dickinson & Co., Orangeburg, N. Y.). The order of the loops was varied, i.e., CT-control-CT-control-CT-control-CT. At the conclusion of all experiments, the volumes remaining in the loops were measured. Biopsies from each loop were taken for cAMP determination. The length of each loop was measured along the antimesenteric border after removal from the animal. Loops that were hemorrhagic were discarded from the study. The results were expressed as milliliters of net fluid movement per centimeter of loop length (net fluid movement = final volume – initial volume [3 ml]). Net secretion into the lumen was expressed as a positive value and net absorption from the lumen was expressed as a negative value. Mean values were obtained for control and CT loops in each animal by averaging the results of the duplicate loops in the same animal.

Intraluminal injection. One group of nine rabbits (nicotinic acid rabbits) was injected subcutaneously with 50 mg/kg nicotinic acid in 8 ml 0.9% saline 3 h and 1 h before the introduction of CT into the loops. This dose is an extrapolation of the dose used in man and rabbits in previously reported antilipolytic studies (5). In view of the relative insolubility of nicotinic acid in aqueous solution (6), nicotinic acid was dissolved in boiling water and maintained at approximately 40°C to prevent crystallization of the nicotinic acid before injection. In the other group of six rabbits (saline rabbits), 8 ml saline alone was administered at the same time intervals used with the nicotinic acid rabbits. In both groups, control and CT solutions were then instilled into their alternate loops and incubation continued for 3 h.

Intraluminal incubation. To determine whether nicotinic acid is effective by the intraluminal route, 50 mg/kg nicotinic acid in 4 ml saline was instilled directly into each of the four intestinal loops of one group of rabbits (nicotinic acid rabbits) 15 min before the introduction of CT. In the other group of rabbits (saline rabbits) 4 ml saline alone was instilled in the loops. After the 15-min interval, the nicotinic acid or saline was flushed out and replaced with 3 ml of electrolyte or CT solutions as in the previous experiments. After 3 h, the volume of intestinal contents and loop lengths was measured and intestinal biopsies were taken for cAMP assay as before.

Dose response of nicotinic acid. To determine the optimal dose of nicotinic acid administered by the intraluminal route on CT-induced secretion, the same procedure as in intraluminal incubation was followed. The nicotinic acid concentration used ranged between 2.5 and 200 mg/kg in each animal.

Reversal of CT-induced changes

The experimental design was similar to the previous experiments and utilized four alternating control and CT loops. In contrast, however, the nicotinic acid was administered by way of an isolated loop rather than directly in the experimental loops. A fifth loop, approximately 20 cm in length, was constructed distally to the experimental loops for the instillation of either 100 mg nicotinic acid/kg in 6 ml RL or RL alone. 3 h after CT and electrolyte solutions had been instilled into the experimental loops, a time at which CT-induced secretion is maximal, nicotinic acid or RL control solution was introduced into the distal 20-cm loop. 1 h later, the residual volumes in the experimental loops and their lengths were measured and biopsies were taken for cAMP assay.

Assays

Full-thickness biopsies for cAMP assay at indicated times were immediately frozen in liquid nitrogen. cAMP was extracted with cold 6% TCA. cAMP levels were assayed by a modification of the binding protein method of Brown et al. (7). Results are expressed as picomoles per milligram protein. Tissue protein was determined by the method of Lowry et al. (8) using standards of bovine serum albumin.

Statistics

Statistical analyses were performed by Student's t test at P < 0.05 for paired and unpaired data (9). All results are expressed as the mean ± 1 SE.

RESULTS

Prevention of CT-induced secretion and elevation of cAMP

Subcutaneous injection. In the saline-injected animals, the net fluid accumulation after 3 h was less in control (containing no CT) than in CT-exposed loops (control, 0.014±0.10 vs. CT, 0.29±0.09 ml/cm; P < 0.001) (Fig. 1). CT also caused a rise in cAMP to levels of 15.15±2.22 pmol/mg protein in contrast to zero time levels of 8.18±1.02 pmol/mg protein and control loop levels of 8.56±2.49 pmol/mg protein (P < 0.001). On the other hand, nicotinic acid pretreatment produced a striking decrease in the CT-induced secretion (control, 0.063±0.098 vs. CT, 0.103±0.072 ml/cm; NS). Nicotinic acid pretreatment also prevented CT-induced elevation of cAMP (control, 8.17±2.95 vs. CT, 8.33±2.19 pmol/mg protein; NS). No statistical difference was found between control and CT loops in the nicotinic acid animals; in fact, there was no statistical difference between the CT loops in the nicotinic acid group and control loops in the saline animals.

Intraluminal instillation of nicotinic acid. To determine whether nicotinic acid pretreatment by the intraluminal route would prevent CT-induced intes-
jejunal secretion, 50 mg/kg nicotinic acid in 4 ml saline was instilled directly in each intestinal loop for 15 min before the instillation of CT or control electrolyte solution. The results of these experiments are similar in every respect to those obtained by pretreatment with a subcutaneous injection. Both CT-induced intestinal secretion and rise in tissue cAMP were prevented by nicotinic acid. In these nicotinic acid-pretreated animals, the rate of secretion and cAMP levels were not significantly different in control and CT loops (secretion-control, 0.18±0.070 vs. CT; 0.23±0.075 ml/cm, NS; cAMP levels-control, 8.3±0.8 vs. CT, 9.5±0.9 pmol/mg, NS) (Fig. 2).

**Effect of nicotinic acid dose by intraluminal route.** The effect of nicotinic acid dose administered intraluminally on the inhibition of CT-induced secretion is shown in Fig. 3. Maximal inhibition was achieved with the dose of 100 mg/kg. This dose was chosen for testing the ability of nicotinic acid to reverse the effects of CT.
Reversal of CT-induced secretion and elevation of cAMP by nicotinic acid

To determine whether nicotinic acid could reverse CT-induced intestinal secretion once it has been initiated, a significant net secretion was induced in RL animals. 4 h after exposure to 50 μg of CT, a secretion of 0.37 ± 0.09 ml/cm was obtained in CT loops in contrast to a secretion of 0.07 ± 0.05 ml/cm in control loops (P < 0.001). Similarly, a concomitant rise in tissue levels of cAMP was obtained in CT loops (17.16 ± 1.16 pmol/mg) whereas control loops were unchanged from zero time (control, 10.17 ± 0.76 vs. zero, 11.8 ± 1.05 pmol/mg; NS) (Fig. 4). On the other hand, after a single dose of 100 mg/kg nicotinic acid was instilled into the distal 20-cm loop 3 h after 50 μg of CT had been instilled into the experimental loop, the 4-h fluid volumes and cAMP levels of CT loops were not significantly different from the values obtained in control loops which have not been exposed to CT (secretion-control, 0.08 ± 0.06 vs. CT, 0.9 ± 0.04 ml/cm, NS; and cAMP-control, 11.8 ± 1.19 vs. CT, 11.88 ± 1.06 pmol/mg, NS) (Fig. 4).

**DISCUSSION**

Fecal water and electrolyte losses accompanying enterotoxigenic diarrhea can be replaced by the use of orally administered electrolyte solutions containing an actively transported solute such as glucose (10). Although therapy is simplified by minimizing the need for intravenous fluid replacement, the duration of diarrhea is not shortened by oral fluid replacement. If an agent capable of inhibiting enterotoxin-induced secretion could be identified that is effective orally, nontoxic, and inexpensive, the therapy of toxigenic diarrhea would be further simplified.

Although a number of agents have been found that will prevent CT-induced intestinal secretion such as cycloheximide (11), polymixin (12), indomethacin (13), aspirin (14), methyl prednisolone (15), ethacrynic acid (16), amphotericin B (17), and propranolol (18), only cycloheximide and methyl prednisolone have been shown to be able to reverse secretion. Our studies have demonstrated that nicotinic acid is also capable of reversing as well as preventing CT-induced secretion.

Butcher et al. (2) have shown that in isolated fat cells, nicotinic acid suppresses the elevated cAMP levels engendered by epinephrine, ACTH, and glucagon and thereby reverses the lipolytic effect of these agents. Nicotinic acid, but not nicatinamide, has been shown to be an effective anti-lipolytic agent (19). Our in vivo studies have shown that nicotinic acid is capable of preventing the elevation of intestinal cAMP and the associated secretion induced by CT. Extrapolating from studies on lipolysis, it is likely that this effect is the result of nicotinic acid rather than one of its metabolites.

Pretreatment of rabbits with nicotinic acid either parenterally or in the intestinal lumen prevents the expected intestinal secretion and elevation of intestinal cAMP that follows exposure to CT (Figs. 1 and 2). In addition the installation of nicotinic acid intraluminally reverses the effects produced by prior exposure to CT (Fig. 4). The small volume remaining at the 4th h in the CT loops of the nicotinic acid-treated animal (1 h after the introduction of nicotinic acid into the distal loop) was unexpected. It was anticipated that the 4th-h volume in the CT loops of the nicotinic acid-treated animals would have been equivalent to the volume found in CT loops of control animals at 3 h. Instead, reabsorption of secreted fluid was observed in the CT loops after instillation of nicotinic acid. These observations, therefore, indicate that not only was secretion inhibited but absorption was stimulated.

The present studies do not provide an explanation for the fluid absorption from the CT loop observed in the hour after the instillation of nicotinic acid. Since the final
volumes in control loops in nicotinic acid-treated animals were similar to those in control loops in untreated animals, nicotinic acid stimulation of absorption cannot be advanced as an explanation of the findings. Although we have not observed nicotinic acid stimulation of absorption in control loops, we have observed an absorptive capacity equivalent to that observed in these experiments in random control animals. It is conceivable that the enhanced absorption seen in the CT loops of the nicotinic acid-treated animals is a result of the presence of a fluid with a more favorable composition than the electrolyte solution instilled into the control loops. Alternatively, CT may stimulate an absorptive process which under usual conditions of study is masked by the greater enhancement of the secretory process. Nicotinic acid may have disproportionately shut off the secretory process in contrast to its effect on the absorptive process. In support of this suggestion are data which show that CT increases absorptive flux (20). Furthermore, elevated levels of cAMP caused by theophylline or CT have been correlated with increased uptake of some neutral and dibasic amino acids (21). Although given little attention in the past, there is, therefore, evidence that CT may enhance absorption and this effect may provide an explanation for our unexpected observations.

The mechanism by which nicotinic acid exerts its effect on CT-induced secretion and elevation of cAMP is not clear. The question of mechanism has not been resolved in the more extensively studied in vitro adipocyte system. Skidmore et al. (3) have reported that nicotinic acid prevents hormonally induced elevation of cAMP by inhibiting adenylate cyclase, whereas Schwabe (4) attributes the effect to stimulation of phosphodiesterase. Since the steps between binding of CT to the intestinal epithelium, the subsequent elevation of cAMP and the stimulation of intestinal secretion have yet to be defined, it is not possible to pinpoint the site of action of nicotinic acid. Nevertheless, it is of interest that Gill and King (22) have presented evidence with pigeon erythrocytes that CT stimulates a NAD-requiring reaction that leads to the formation of a permanently activated adenylate cyclase. More recently, evidence has been presented invoking a NADase activity (23) for CT analogous to that which has been so elegantly proven for diphtheria toxin (24). Whether or not nicotinic acid or one of its metabolites inhibits the postulated CT NADase activity remains to be determined. Another mechanism by which CT increases adenylate cyclase activity has been reported to be prevention of the hydrolysis of the bond between adenylate cyclase and guanosine triphosphate, a step which has been proposed as the turn off mechanism that returns activated adenylate cyclase to the basal inactive state (25).

Regardless of which mechanism is acting, the results of these experiments suggest that nicotinic acid might be effective in controlling diarrhea associated with cholera and possibly other diarrheal disorders associated with elevated levels of cAMP. Nicotinic acid has been used therapeutically in man as an antilipolytic agent. To what extent the effects of nicotinic acid described here, in rabbits, can be extrapolated to humans in the treatment of diarrheal diseases remains to be examined.

ACKNOWLEDGMENTS

We wish to thank Dr. Naji Sahyoun for his suggestions for potential inhibitors of adenylate cyclase.

This study was supported by Commonwealth Exchange Program W76-2002 and by National Institutes of Health grant AI-08187.

REFERENCES


